Introduction
Clinoscope Services Limited, a substantial shareholder in Neimeth International Pharmaceuticals Plc, has increased its stake in the Nigerian drugmaker through a significant share purchase. The investor acquired more than 74 million ordinary shares in a transaction valued at approximately N448.36 million, as disclosed in a regulatory filing submitted to the Nigerian Exchange. The acquisition arrives as Neimeth reports a return to profitability in its 2025 financial year following losses in the prior period.
What Happened
The purchase was executed in Lagos on November 10, 2026, at a price of N6 per share. Clinoscope bought a total of 74,726,661 ordinary shares for roughly N448.36 million. The deal was reported through an insider share-dealing notification filed with the NGX on November 13, 2026, and signed by Neimeth's Company Secretary, Chinenye S. Adekanmbi. The filing was classified as an initial notification of share dealing by an insider. The disclosure did not specify how many shares Clinoscope held before the transaction or what percentage of the company it owns afterward.
Why This Matters
The move reflects confidence from a major investor at a critical juncture for Neimeth. The pharmaceutical company returned to profit in 2025, recording a pre-tax profit of N1.49 billion after posting a pre-tax loss of N854.43 million in 2024. Revenue surged 64 percent to N7.37 billion, driven primarily by its pharmaceutical segment, which contributed N7.18 billion. Gross profit climbed to N3.35 billion, while operating profit rose to N2.71 billion from N18.89 million the previous year.
Despite the earnings rebound, financial pressures persist. External debt increased to N9.68 billion from N5.36 billion, and cash and cash equivalents declined to N1.61 billion from N2.15 billion. Shareholders have also backed an expanded N50 billion fundraising mandate, giving the board flexibility to raise capital through public offerings, rights issues, private placements, commercial papers, bonds, and other instruments, pending regulatory approvals.
Key Takeaways
- Clinoscope Services Limited purchased 74,726,661 Neimeth shares at N6 per share.
- The transaction was valued at approximately N448.36 million and took place on November 10, 2026.
- Neimeth returned to profitability in 2025 after recording losses in 2024.
- Pre-tax profit reached N1.49 billion, while revenue grew 64 percent to N7.37 billion.
- Shareholders approved a N50 billion fundraising mandate to support expansion, including a planned manufacturing plant in South-East Nigeria.
- Neimeth shares closed at N7.20 on November 13, 2026, reflecting a 24.14 percent year-to-date gain.
Conclusion
Clinoscope's additional share purchase signals renewed investor confidence in Neimeth International Pharmaceuticals as the company moves beyond a difficult financial period. With improved earnings, a broader fundraising mandate, and plans to expand production capacity and product lines, the drugmaker is positioning itself for future growth. However, rising debt and shrinking cash reserves mean investors and analysts will likely monitor upcoming disclosures and operational developments closely.

Discussion
Join the conversation
Thoughtful reactions, questions, and follow-up ideas help shape the next story.